Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks
- Authors
- Kim, Sin Gon; Kim, Kyoung Jin; Yoon, Kun Ho; Chun, Sung Wan; Park, Kyong Soo; Choi, Kyung Mook; Lim, Soo; Mok, Ji-Oh; Lee, Hyoung Woo; Seo, Ji A.; Cha, Bong-Soo; Kim, Mi Kyung; Shon, Ho Sang; Choi, Dong Seop; Kim, Doo Man
- Issue Date
- 10월-2020
- Publisher
- WILEY
- Keywords
- clinical trial; lobeglitazone; randomized trial; thiazolidinediones; type 2 diabetes
- Citation
- DIABETES OBESITY & METABOLISM, v.22, no.10, pp.1869 - 1873
- Indexed
- SCIE
SCOPUS
- Journal Title
- DIABETES OBESITY & METABOLISM
- Volume
- 22
- Number
- 10
- Start Page
- 1869
- End Page
- 1873
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/130458
- DOI
- 10.1111/dom.14085
- ISSN
- 1462-8902
- Abstract
- We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were -0.79% and -0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, -0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (-11.9% vs. -4.8%;P < .0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.